The aim of this study is to analyze a group of patients with chronic lymphoproliferative disorders associated with B, C, D hepatitis viral infection. This group of chronic lymphoproliferative disordered patients with associated hepatitis viral infection has been diagnosed and monitored in the Hematology Department of the University Emergency Hospital of Bucharest, between December 2007 and January 2009. Our study is meant to observe the influence of the viral infection on clinical and biological evolution of the enrolled patients.
Background

HBV infections and chronic lymphoproliferative disorders
The hepatitis viral infections are frequent in patients with chronic lymphoproliferative disorders, being involved in their pathogeny and contributing to the morbidity and mortality of these patients. HBV acute infection could evolve to spontaneous recovery in 90% of the cases or could become a chronic infection, the risk decreasing with age (5-10% in adults). The risk is higher in immunosupressed patients. Due to the fact that HBV has a special hepatic tropism, it was revealed that there are small quantities of non-replicative HBV-DNA or viral antigens in mononuclear cells from peripheral blood such as monocytes, B-lymphocytes, CD4 and CD8 Tlymphocytes, leading to the idea that the lymphocytes represent an extrahepatic viral reservoir.
HCV infection and chronic lymphoproliferative disorders
The HCV acute infection is asymptomatic in 75% of the cases, becoming chronic in 80% of the cases, much more frequent than HBV infection, and evolving to hepatic cirrhosis in a period of 5-30 years. HCV is a hepatotrop virus, but it is able to infect and replicate in hematopoietic cells, a lot of studies showing the presence of RNA-HCV within B, T-lymphocytes and monocytes in patients with HCV infection.
Objectives
We have performed a retrospective and prospective study of patients with CLD associating hepatitis viral infections diagnosed in the Hematology Department of SUUB starting with December 2007. The objectives included the positive diagnosis of chronic lymphoproliferative disorder, the statistic analysis of clinical and biological parameters, the correlations between these parameters and the identification of prognostic markers.
The positive diagnosis was established according to the International Guidelines:
1. For chronic lymphocytic leukemia (CLL), after National Cancer Institute (NCI) (7) -lymphocytosis > 5 x 10 9 /L in peripheral blood and confirmation by flowcytometry of lymphocytes [1] .
2. For non-Hodgkin's lymphoma (NHL) -by assessing the malignant lymphoid population with special immunophenotype, by immunohystochemistry or immunophenotyping, using modified REAL [2] and WHO classifications [3, 4] .
The inclusion criteria are: positive diagnosis of a B or T chronic lymphoproliferative disorder (established on leukocytosis with lymphocytosis, flow-cytometry on peripheral blood or bone marrow, bone marrow aspirate, bone marrow biopsy, lymph node biopsy, immunohystochemistry) and infection with hepatitis viruses (B, C, D).
The exclusion criteria was the absence of hepatitis viruses infection.
Material and methods
We monitored clinical parameters, obtained from patients' files, such as B signs (weight loss > 10% from body weight, fever, sweats), the presence of adenopathies, hepatomegaly, splenomegaly, the extranodal and bone marrow involvement, the clinical signs of liver disease (jaundice, peritoneal liquid, collateral circulation). The biological parameters monitored were:
-anemia -Hb < 11 g/dl -thrombocytopenia PLT < 150.000/mm³ -lymphocytosis > 20% lymphocytes -presence of autoimmune hemolytic anemia -the value of serum LDH -kidney tests (BUN, creatinine), uric acid -liver tests (GOT, GPT, alkaline phosphatase, GGT), total bilirubine with fractions -the presence of cryoglobulins -coagulation changes The blood cell count was performed in the Hematology Laboratory of The Hematology Department of University Emergency Hospital of Bucharest, including the morphologic analysis of the blood smear. The biochemical tests were performed in the Laboratory of SUUB.
Results
The patients enrolled in this analysis were diagnosed and monitored in our department from December 2007 until January 2009.
In the group, there were 41 patients with CLD and B/C/D hepatitis viral infection, among whom 25 females (25/41=60,97%) and 16 males (16/41=39,02%). The median age of the group was of 64 (min 30, max 85) years old, and the patients' distribution according to the age was: 20-50 years old -6/41 (14,63%) patients, 51-70 years old -23/41 (56,09%) patients and over 70 years old -12/41 (29,26%) patients. The epidemiologic investigation revealed that 4/41 (9,73%) patients had received blood transfusions before, 15/41 (36,58%) patients had surgery (apendicectomy, ovarectomy, gastrectomy, diagnosis or therapeutic splenectomy, laborious teeth surgery) and 4/41 (9,75%) patients associated both epidemiologic conditions for hepatitis viral infection.
Within the analyzed group, the predominant was the B-cell lineage -39/41 (95,12%) patients, and, the Tcell lineage was found in only 2/41 (4,87%) patients.
The patients' distribution according to the histological type of CLD is the following: diffuse large Bcell non-Hodgkin lymphoma -13/41 (31,70%) patients, small B-cell NH lymphoma -11/41 (26,82%) patients, follicular NH lymphoma -3/41 (7,31%) patients, lymphoblastic lymphoma -1/41 (2,43%) patients, T-cell NH lymphoma -2/41 (4,87%) patients, Hodgkin's lymphoma -2/41 (4,87%) patients, chronic lymphocytic leukemia -7/41 (17,07%) patients and Waldenstrom disease -2/41 (4,87%) patients.
The aggressive form of CLD was found in 19/41 (46,34%) patients and the indolent type (non-aggressive) in 22/41 (63,5%) patients.
The hepatitis viral infections associated in our group were: HBV infection in 14/41 (34,14%) patients, HCV infection in 24/41 (58,53%) patients, the double association HBV + HDV in 1/41 (2,43%) patients, HBV + HCV in 1/41 (2,43%) patients and the triple association HBV + HCV+ HDV also in 1/41 (2,43%) patients. The extra-nodal involvement was present in 10/41 (24,39%) patients; 4/41 (9,75%) patients with HBV infection and 6/41 (14,63%) patients with HCV infection. The clinical signs of hepatic failure were found in a small number of patients, such as: jaundice -3/41 (7,31%), bleedings -2/41 ( 4,87%), peritoneal effusion -1/41 (2,43%), collateral circulation -3/41 (7,31%).
The hematological parameters: the median hemoglobin was 12 (min 8,5, max 17,4), normal ranges being 11-15 g/dl. In our group of patients -9/41 (21,95%) had anemia (Hb < 11 g/dl), 4/9 (44,44%) patients had HBV infection and HCV infection, and 1/9 (11,11%) had triple viral association (HBV+HVC+HDV). We had lymphocytosis in 33/41 (80,48%) patients; 13/33 (39,39%) -aggressive type of CLD: 4/13 (30,76%) patients were HBV infected, 8/13 (61,53%) were HCV infected and 1/13 (7,69%) patients were HBV+HCV infected; 20/33 (60,60%)-had the indolent type of CLD: 5/20 (25%) patients were HBV infected, 13/20 (65%) patients were HCV infected, 1/20 (5%) patients were HBV+HDV infected and 1/20 (5%) patients were HBV+HCV+HDV infected. Thrombocytopenia (ranges under 150.000/mm³) was revealed in 13/41(31,70%) patients. In this group, the patients had: 7/13 -had an aggressive type of CLD , from which 4/7 (57,14%) patients were HBV infected and 3/7 (42,85%) were HCV infected; 6/13 patients had an indolent type of CLD associated in 2/6 (33,33%) patients with HBV infection, 2/6 (33,33%) patients had HCV infection, 1/6 (16,66%) patients had double HBV+HDV infection and 1/6 (16,66%) patients had triple HBV+HCV+HDV infection. High values of GOT (normal ranges 10-40 U/L) were revealed in 27/41 (65,85%) patients with: HBV infection 6/27 (22,22%), HCV infection 19/27 (70,37%), HBV+HDV 1/27 (3,70%) and HBV+ HCV 1/27 (3,70%) patients. In our group, GPT was over normal (normal ranges 10-37 U/L) found in 32/41 (78,04%) patients, out of whom 21/32 (65,62%) had HCV infection, 10/32 (31,25%) HBV infection and 1/32 (3,12%) patients double infection HBV+HCV. Only 8/41 (19,5%) patients had over normal serum alkaline phosphatase (normal ranges 40-150 U/L), out of whom 6/8 (75%) had HCV infection and only 2/8 (25%) had HBV infection. Monitoring the GGT levels, we observed high values (normal ranges 9-64 U/L) in 23/41 (56,09%) patients, most with HCV infection 14/23 (60,86%). The total bilirubine was high in 12/41 (29,2%) patients, most with HCV infection also 4/12 (58,33%) patients.
The serum LDH, an important prognostic and activity marker of the hematological disease, was high in 17/41 (41,46%) patients, out of whom 9/17 patients have an aggressive type of CLD associating the HBV infection in 3/9 (33,33%) patients, 5/9 (55,55%) patients had HCV infection and one of them associated a double infection HBV+HCV 1/9 (11,11%). The other 8 patients with elevated serum LDH have an indolent type of CLD: 3/8 (37.5%) patients with HBV infection and 5/8 (62,5%) patients with HCV infection. 
Therapy
The patients' therapy was also monitored. Thus, antiviral therapy was received by 12/41 (29,2%) patients: Lamivudine 8/41 (19,51%) patients, Ribavirine/Interferon 4/41 (9,75%) patients. Chemotherapy was administered to 32/41 (78,04%) patients: 5/41 (13,19%) had monotherapy (alkilant agents) and 27/41 (65,85%) patients received combined chemotherapy (CVP/CHOP/CHOEP +/-Rituximab, Fludarabine). We have to mention that 7/41 (17,07%) patients associated Rituximab -2 patients with HCV infection and 5 with HBV infection. Chemotherapy associated to antiviral therapy was received by 9/41 (21,95%) patients, most of them with HBV infection 6/9 (66,66%).
Discussions
Although HBV has a special hepatic tropism, it was revealed that there are small quantities of nonreplicative HBV-DNA or viral antigens in mononuclear cells from peripheral blood such as monocytes, Blymphocytes, CD4 and CD8 T-lymphocytes, leading to the idea that the lymphocytes represent an extrahepatic viral reservoir. The mechanism through which the viral genom persists and replicates within lymphocytes is yet not known. HBV could replicate in extrahepatic tissues like bone marrow and lymph nodes, being involved in extrahepatic pathology. An association of 30% between HBV and chronic lymphoproliferative disorders was demonstrated and cryoglobulins were found in 15% of the patients with HBV infection [5] .
The reactivation of HBV infection could be the result of chemotherapy in patients with CLD associating HBV infection, but immunosuppression induced by CLD could be an independent risk factor for the reactivation [6] . The mechanism of viral reactivation represents the activation and increase of viral replication during immunosuppressive therapy, revealed by serum increase of DNA-HBV, the serum presence of AgHBe, followed by immune response mediated by T-lymphocytes, leading to an immune mechanism that destroys the infected hepatocytes. An analysis of the risk to develop a B-cell lymphoproliferative disorder in AgHBs positive patients showed that the risk of infection or viral reactivation is increased because of the direct immunosuppressive effect of the chronic lymphoproliferation and, also, HBV could have a part in lymphomagenesis through the persistence of small quantities of DNA-HBV in peripheral mononuclear cells, leading to a chronic stimulation of Bcells and clonal transformation in time [6] .
As for the HCV, it was considered that the Bclone proliferation is happening in bone marrow and liver, as a response to chronic stimulation by HCV antigens such as E2 protein, this stimulated clone having a high risk of malignant transformation. The E2 protein has the binding site CD 81, representing the specific hepatocyte and B-lymphocyte receptor for HCV. The mechanism through which the HCV is leading to a chronic lymphoproliferative disorder is thought to be the chronic stimulation of B-lymphocytes through immune mechanisms [7] .
Moreover, it was demonstrated that the HCV infected patients present the translocation involving the oncogene bcl-2 within their peripheral B-lymphocytes, representing a high risk of developing a non-Hodgkin lymphoma.
A high prevalence of HCV antibodies and/or RNA-HCV in B-cell NHL patients was revealed and it was frequently associated with the mixed essential cryoglobulinemia. The exact relationship between HCV and cryoglobulinemia is not yet known, but it is certain that HCV is a chronic stimulus and that cryoglobulins are present in 50% of the HCV patients [8] . In HCV infection, we find autoimmune phenomena even in the absence of cryoglubulinemia and HCV could induce chronic lymphoproliferations [9] . The risk factors for cryoglobulinemia in HCV infected patients are: female sex, alcohol abuse, detectable RNA-HCV in serum, high gammaglobulins, high rheumatoid factor [5] .
The association of HCV infection with T-cell nonHodgkin's lymphomas and Hodgkin's lymphoma is not evident; only 5% of the patients were found with HCV infection and Hodgkin's disease [10] .
Succesive studies made by Zignego et all in 1995 [11], 1996 [12] and 1997 analyzed HCV viremia in 35% patients with B-cell NHL, the most involved genotypes being 1b (61% of cases) and 2a (14% of cases). HCV was more frequent in low-grade malignity lymphomas. Other studies [13, 14, 15] do not reveal a higher prevalence of HCV infection in NHL patients, suggesting that HCV infection -NHL association is strictly related to geographic prevalence of HCV infection.
Most of the studies showed the relationship between HCV and low grade NHL, especially immunocytoma, but there is also a strong association with marginal lymphoma -Saadoun et al (2005) 
Conclusions
The preliminary results of our study are in agreement with the literature data. A high frequency of chronic lymphoproliferative disorders associated with hepatitis virus infections was found in women, especially over 50 years old. B-cell CLD was the most frequent associated with hepatitis viral infection. In our group, the HCV infection is the most frequent hepatitis virus infection and highly associated with the non-aggressive histological type of CLD, the presence of adenopathies, hepatomegaly, splenomegaly and extra-nodal involvement. The lymphocytosis is significantly correlated with the HCV infection; the autoimmune phenomena were rare and found only in HCV infected patients. Moreover, the liver status was modified more, within the same subgroup of patients.
All clinical, hematological and biochemical parameters will be analyzed in dynamics and correlated with the administered therapy and the dynamics of the disease course.
